All Articles

Anyone, regardless of their pre-existing physical or mental health issues, can get cancer.

FDA Grants Priority Review to Application for Pembrolizumab Monotherapy as First-Line Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)

Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).

Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.

Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.

Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).

The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus stan­dard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).

A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.

The following research abstracts in lung cancer were accepted by the Academy of Oncology Nurse & Patient Navigators for the 2018 Annual Conference. We congratulate the authors on their work and the impact they have had on the field of navigation.